SCHEMBL5502502

SCHEMBL5502502

CC(=O)n1nc(C)c(Br)c1C

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 2/20 0.66
MAP3K14 Q99558 2/20 0.66
IKBKE Q14164 1/20 0.66
ALDH1A1 P00352 4/20 0.50
KMT2A Q03164 4/20 0.50
POLB P06746 2/20 0.50
PLAU P00749 1/20 0.50
ELANE P08246 1/20 0.50
MCL1 Q07820 1/20 0.50
MAPT P10636 1/20 0.47
MEN1 O00255 3/20 0.46
CYP2C19 P33261 2/20 0.46
CYP2D6 P10635 1/20 0.46
TP53 P04637 2/20 0.45
MAPK1 P28482 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
HTT P42858 1/20 0.44
APAF1 O14727 1/20 0.43
LMNA P02545 1/20 0.42
CYP1A2 P05177 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7457886 0.74 ALDH1A1 (0.56) IKBKBMAP3K14IKBKEALDH1A1KMT2A
SCHEMBL3985184 0.74 MAP3K14 (0.46) IKBKBMAP3K14IKBKEALDH1A1KMT2A
SCHEMBL3231153 0.74 ALDH1A1 (0.47) IKBKBMAP3K14IKBKEALDH1A1KMT2A
SCHEMBL9123113 0.72 IKBKB (0.44) IKBKBMAP3K14IKBKEALDH1A1KMT2A
SCHEMBL15273764 0.71 IKBKB (0.51) IKBKBMAP3K14IKBKEALDH1A1KMT2A
SCHEMBL27630809 0.69 IKBKB (0.42) IKBKBMAP3K14IKBKEALDH1A1KMT2A
SCHEMBL15231004 0.69 APAF1 (0.56) IKBKBIKBKEALDH1A1KMT2APOLB
SCHEMBL32666122 0.69 ALDH1A1 (0.52) IKBKBIKBKEALDH1A1KMT2APOLB
Nitric Acid SCHEMBL9122464 0.67 MAPT (0.49) IKBKBMAP3K14IKBKEALDH1A1KMT2A
SCHEMBL3585241 0.65 ALDH1A1 (0.67) ALDH1A1KMT2AMEN1CYP2C19CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7473790-B2 Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same PFIZER INC. (US) 2009-01-06 US disclosed
US-7473790-B2 Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same PFIZER INC. (US) 2009-01-06 US disclosed
US-20070254917-A1 INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS LIGAND PHARMACEUTICALS INC. 2007-11-01 US disclosed
EP-1778233-A1 INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS LIGAND PHARMACEUTICALS, INC. (US) 2007-05-02 EP disclosed
WO-2006019716-A1 INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS LIGAND PHARMACEUTICALS, INC. (US) 2006-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254917-A1 INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS CASR, GRK2, RYR2 IKBKB 490/4885MAP3K14 1105/4885IKBKE 495/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.